Blood cancer drug safety tracked over 5 years
NCT ID NCT07162181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment every 12 weeks for about 5 years. The main goal is to track serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer hospital
Beijing, 100142, China
-
Blood Institute of the Chinese Academy of Medical science
Tianjin, 300020, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Shanghai East Hospital
Shanghai, 200123, China
-
Sun Yat-sen University Cancer Center
Guangzhou, 510060, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a single shot build a cancer army inside the body?
- Rare childhood bone lymphoma: can past cases guide future care?
- New pill targets Hard-to-Treat lymphoma in early human test
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure